NP Rank:
Pfizer in Buyout Talks with Wyeth
According to these reports, Big Pharma is going to become Huge Pharma: Pfizer is in buyout talks with Wyeth. The result has seen stocks throughout the pharmaceutical industry on the rise.
One result of the merger would be a stop-loss for when Pfizer's patent on Lipitor runs out... while Pfizer is known for a particular blue pill, Lipitor (a cholesterol-control medicine) accounts for a quarter of its annual revenue. Pfizer also makes Celebrex, an arthritis medication; and Xanax, which was developed to treat panic disorders.
Wyeth isn't a household name, but its flagship pain reliever, Advil, certainly is, as is the Centrum line of multivitamins. You probably have Chapstick in your jacket, as well.
Some of you also may have learned, the hard way, about Wyeth's antivenin for the North American Coral Snake.
There is also talk of layoffs within Pfizer as the recession hits its bottom line; when we hear more about that, we'll post it in the Layoffs Channel.
Shares in drug stocks around Europe gain after the Wall Street Journal reports on its Web site that Pfizer (PFE.N), the world's largest drugmaker by revenue, is in talks to acquire rival Wyeth (WYE.N).
Pfizer, based in New York, has been talking with Madison, New Jersey-based Wyeth for months, the person said. A combination would create a drugmaker with annual sales of more than $70 billion and best-selling medicines including the cholesterol pill Lipitor and the Prevnar vaccine against pneumonia.







Most RecentMost Recommended Comments (2)
at 09:30 on January 23rd, 2009
I am not fund of that news, less independent labs means more narrow research and less objectivity.
at 09:43 on January 23rd, 2009
The best part was when they put 2400 people out of their jobs here in my hometown when they closed a massive research lab. How great to know they've got money to burn on acquisitions and are meanwhile just contributing to unemployment.
The Constant Gardner was based on these guys. What a great track record.